Make Informed Investment Decisions with Affordable Access to Experts
Nonalcoholic Steatohepatitis (NASH): What’s the Market Opportunity and Who are the Major Players?Ticker(s): AGN, ICPT, GNFTF, GLMD, CNAT, GILD
Name: Dr Joseph Lim - MD
Institution: Yale University
- Academic hepatologist, Associate Professor of Medicine (Digestive Diseases) and Director, Yale Viral Hepatitis Program.
- Treats patients with chronic liver diseases including the entire spectrum from cirrhosis, liver failure, and post-transplant; Approximately 5-10% of his patients have chronic pruritus symptoms, 200 patients with biopsy-proven NASH and a larger cohort of NAFLD, and 70 patients with PBC/PSC.
- Has served on the national steering committees for large observational cohort studies for liver disease and has published over 100 papers in the area of GI and liver diseases.
Get complimentary access to this call. Click orange "Subscribe to Access" button and enter coupon code Freemo_Starter
What is your background treating serious liver diseases? How many patients do you treat with NASH?Added By: kcmckee
What current recommendations are you making to patients with NASH when there are no FDA approved treatments?Added By: kcmckee
NASH sounds like it is frequently left undiagnosed. Why do you think this is, and do you see this changing at all in the future? What do you think this means for the potential NASH market?Added By: kcmckee
Generally speaking, what categories of NASH drug do you think hold the most potential? What in the data leads you to believe these will be the most effective treatments?Added By: kcmckee
What are your thoughts on the NASH drugs being developed by GILD, AGN, ICPT, GLMD, GNFT, and CNAT? Are there other major companies you think investors should keep an eye on?Added By: kcmckee
Overall, what drugs do you think hold the most potential for treating NASH? Why?Added By: kcmckee
Some estimates have proposed a $20 billion NASH market by 2025. Does this sound plausible in your opinion?Added By: kcmckee
How much potential do you think NASH drugs have for treating other fatty liver diseases? Do any of the aforementioned companies have a product you think would lend itself especially well to treating other serious liver conditions?Added By: kcmckee
How will future therapies be spread across different call points? Will they all be prescribed by GPs? Which will likely be prescribed with a gastroenterologist or hepatologist?Added By: userde43a902
Once a patient has been started on a future med, do you think it is practical (and economically feasible) to do annual / semi-annual follow-up monitoring with the traditional scanning technologies and tissue biopsy ? Surely payers will expect long-term monitoring of patient disease progression/ regression while on therapy ? What about the potential for liquid biopsies now in research or being used in Europe?Added By: user6f5a2920
Is there any work going on to develop a better diagnostic test for NASH that does not require a biopsy?Added By: userc268134d
Given the low rate of diagnosis of NASH and limited number of experienced investigators, enrollment of all the competing trials for these drugs is expected to be a major challenge.
Are you aware of any companies using novel approaches to overcome this challenge, or do you have any ideas on what companies could do to successfully meet their enrollment goals?
Many laboratories are focusing on NASH induced Fibrosis (CNAT emricasan ,
GILEAD simtuzumab, Tobira cenicriviroc) Do you think it is logical to treat the
consequences of NASH (fibrosis and cirrhosis) without treating the cause ( metabolic NASH) ?
If as seen in HEP C, a liver with less than 70% of advanced fibrosis can
regenerate if the HEP C ( the cause ) is cured, do you think that a drug targeting
metabolic causes of NASH could induce a fibrosis reversion ?
Your views on endoglin expression and its relationship to fibrosis, and the possible use of endoglin antibodies to
reverse or stop fibrosis?
Cempra recently presented some interesting preliminary data in NASH patients treated with their new antbiotic
solithromycin. Have you seen the data? Any thoughts?
many trials , serological markers were well improved as histological markers
were less improved. Do you think that
biopsy representing 1/50000 of the liver mass is representative of the
liver state ?
Do you think that composite endpoints mixing histological and metabolic markers could be more representatives of the liver state ?
Over the past 18 months, leading KOLs and other NASH experts have moved away from NAS score alone (two-point improvement) endpoint .Today the two approvable surrogate endpoints for NASH are composites: 'complete resolution of steatohepatitis and no worsening of fibrosis', or 'at least one-point improvement in fibrosis with no worsening of steatohepatitis' 1 - The FLINT results were based on the NAS score two-point improvement and not on the current required endpoints for Phases 3, moreover, OCA failed to reach those endpoints in the Japanese study. Could this make difficult to OCA to reach the new endpoints in their ‘Regererate’ Study ? 2 – why many new 2b trials launched in 2016 still use NAS score two-point improvement as endpoint, is it because it is an easier endpoint to reach than the new required NASH reversion ( 0 in ballooning and 0-1 in inflammation) .Added By: gdivry
More specifically, regarding the diagnosis of NASH, should we expect Fibroscan or, something like it, to become the standard of care or; will biopsy still be the final say in determining a final/confirmed NASH diagnosis?Added By: user4ca005c0
think that taking statins could interfere or impact results in NASH trials
The most advanced compounds in NASH pipeline are an FXR agonist (OCA) and a PPAR alpha /delta (Elafibranor) with different targets and effects
Do you think that a combo with those two drugs could be pertinent and efficient ?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.